Month: January 2021

Addition Of Wee1 Inhibitor To Gemcitabine Reduces Risk Of Disease Progression And Death In Women With Recurrent, Platinum-Resistant Or -Refractory Ovarian Cancer In Phase 2 Trial

MedPage Today (1/25, Ingram) reports researchers found in a phase 2 trial that the addition of “the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer.” The trial’s results were published in The Lancet. […]

Read More

US Reports Another Record One-Year Decline In Cancer Death Rate From 2017 To 2018

The AP (1/12, Stobbe) reports the US “reported another record one-year decline in the…cancer death rate, a drop they attribute to success against lung cancer.” The US cancer death rate has been decreasing since 1991, and “from 2017 to 2018, it fell 2.4%, according to an American Cancer Society report, topping the record 2.2% drop reported the year […]

Read More

CRT Improves DFS And OS In Patients With Stage IIIB Cervical Cancer In Long-Term Follow-Up To Phase 3 Trial

Cancer Therapy Advisor (1/7, Lawrence) reports researchers found in a long-term follow-up of a phase 3 trial that “in addition to improving disease-free survival (DFS), chemoradiotherapy (CRT) resulted in an overall survival (OS) benefit for patients with stage IIIB cervical cancer.” The researchers say the results “reinforce the evidence that CRT for the treatment of stage […]

Read More

Decline In Preventative Cancer Screenings Due To Pandemic May Have Serious Implications For Years To Come

Forbes (1/4) contributor Alice Broster writes, “In early 2020 many hospitals and clinics put preventative cancer screenings on hold due to the pandemic” and instead urged the use of “telehealth services as much as possible.” Broster adds that although “many clinics have opened their doors for cancer screenings again research suggests there’s been a drop in […]

Read More